» Articles » PMID: 34270968

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2021 Jul 16
PMID 34270968
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Low-dose chest CT screening for lung cancer has become a standard of care in the United States, in large part because of the results of the National Lung Screening Trial (NLST). Additional evidence supporting the net benefit of low-dose chest CT screening for lung cancer, and increased experience in minimizing the potential harms, has accumulated since the prior iteration of these guidelines. Here, we update the evidence base for the benefit, harms, and implementation of low-dose chest CT screening. We use the updated evidence base to provide recommendations where the evidence allows, and statements based on experience and expert consensus where it does not.

Methods: Approved panelists reviewed previously developed key questions using the Population, Intervention, Comparator, Outcome format to address the benefit and harms of low-dose CT screening, and key areas of program implementation. A systematic literature review was conducted using MEDLINE via PubMed, Embase, and the Cochrane Library on a quarterly basis since the time of the previous guideline publication. Reference lists from relevant retrievals were searched, and additional papers were added. Retrieved references were reviewed for relevance by two panel members. The quality of the evidence was assessed for each critical or important outcome of interest using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Meta-analyses were performed when enough evidence was available. Important clinical questions were addressed based on the evidence developed from the systematic literature review. Graded recommendations and ungraded statements were drafted, voted on, and revised until consensus was reached.

Results: The systematic literature review identified 75 additional studies that informed the response to the 12 key questions that were developed. Additional clinical questions were addressed resulting in seven graded recommendations and nine ungraded consensus statements.

Conclusions: Evidence suggests that low-dose CT screening for lung cancer can result in a favorable balance of benefit and harms. The selection of screen-eligible individuals, the quality of imaging and image interpretation, the management of screen-detected findings, and the effectiveness of smoking cessation interventions can impact this balance.

Citing Articles

Aggressively Quick: A Case of Negative Radiographic Evidence Progressing to a Large Lobulated Lung Mass In Six Months.

Alyassin N, Zakharia K, Yusuf M, Prabhakar L, Ismail M Eur J Case Rep Intern Med. 2025; 12(3):005184.

PMID: 40051736 PMC: 11882009. DOI: 10.12890/2025_005184.


A Novel Automated Algorithm to Identify Lung Cancer Screening from Free Text of Radiology Orders.

Rustagi A, Vali M, Graham F, Lum E, Slatore C, Keyhani S J Gen Intern Med. 2025; .

PMID: 40000524 DOI: 10.1007/s11606-025-09429-2.


Peripheral Extracellular Vesicles for Diagnosis and Prognosis of Resectable Lung Cancer: The LUCEx Study Protocol.

Rodriguez-Sanz J, Munoz-Gonzalez N, Cubero J, Ordonez P, Gil V, Langarita R J Clin Med. 2025; 14(2).

PMID: 39860417 PMC: 11765880. DOI: 10.3390/jcm14020411.


Clinical effect of Almonertinib in treating epidermal growth factor receptor mutation-positive residual ground-glass opacities after stage I lung cancer resection.

Zhang J, Zhang Z, Zhou Y, Huang C Am J Transl Res. 2025; 16(12):7553-7562.

PMID: 39822544 PMC: 11733316. DOI: 10.62347/TOYK7025.


Economic Evaluation of a Novel Lung Cancer Diagnostic in a Population of Patients with a Positive Low-Dose Computed Tomography Result.

Morris M, Habib S, Do Valle M, Schneider J J Health Econ Outcomes Res. 2025; 11(2):74-79.

PMID: 39810799 PMC: 11731590. DOI: 10.36469/001c.121512.


References
1.
Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

2.
Leleu O, Basille D, Auquier M, Clarot C, Hoguet E, Petigny V . Lung Cancer Screening by Low-Dose CT Scan: Baseline Results of a French Prospective Study. Clin Lung Cancer. 2020; 21(2):145-152. DOI: 10.1016/j.cllc.2019.10.014. View

3.
Mitchell A, Gandhi A, Scott-Coombes D, Perros P . Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S150-S160. PMC: 4873931. DOI: 10.1017/S0022215116000578. View

4.
Menezes R, Roberts H, Paul N, McGregor M, Chung T, Patsios D . Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. Lung Cancer. 2009; 67(2):177-83. DOI: 10.1016/j.lungcan.2009.03.030. View

5.
Andrews J, Guyatt G, Oxman A, Alderson P, Dahm P, Falck-Ytter Y . GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66(7):719-25. DOI: 10.1016/j.jclinepi.2012.03.013. View